CA1142855A - Compose anti-tumoral et procede de preparation - Google Patents

Compose anti-tumoral et procede de preparation

Info

Publication number: CA1142855A
Authority: CA; Canada
Prior art keywords: solution; chlorhydrate; ethanol; amino; boric acid
Prior art date: 1979-06-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000354516A

Other languages

English (en)

Inventor

Dimitrie Ranetescu (Deceased)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CENTRALA INDUSTRIALA DE MEDICAMENTE COSMETICE COLORANTI SI LACURI BUCURESTI

Original Assignee

CENTRALA INDUSTRIALA DE MEDICAMENTE COSMETICE COLORANTI SI LACURI BUCURESTI

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-06-23

Filing date

1980-06-20

Publication date

1983-03-15

1980-06-20 Application filed by CENTRALA INDUSTRIALA DE MEDICAMENTE COSMETICE COLORANTI SI LACURI BUCURESTI filed Critical CENTRALA INDUSTRIALA DE MEDICAMENTE COSMETICE COLORANTI SI LACURI BUCURESTI

1983-03-15 Application granted granted Critical

1983-03-15 Publication of CA1142855A publication Critical patent/CA1142855A/fr

Status Expired legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 6
230000000259 anti-tumor effect Effects 0.000 title claims abstract description 4
238000000034 method Methods 0.000 title claims description 12
230000008569 process Effects 0.000 title claims description 4
238000002360 preparation method Methods 0.000 title claims description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 26
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
WXZGVQHBPNZQFD-UHFFFAOYSA-N ClO.NC1=CC=C(C(=O)C(C)(O)N(CC)CC)C=C1 Chemical compound ClO.NC1=CC=C(C(=O)C(C)(O)N(CC)CC)C=C1 WXZGVQHBPNZQFD-UHFFFAOYSA-N 0.000 claims abstract description 11
239000004327 boric acid Substances 0.000 claims abstract description 11
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
235000010323 ascorbic acid Nutrition 0.000 claims abstract description 7
239000011668 ascorbic acid Substances 0.000 claims abstract description 7
229960005070 ascorbic acid Drugs 0.000 claims abstract description 7
239000011780 sodium chloride Substances 0.000 claims abstract description 7
239000012153 distilled water Substances 0.000 claims abstract description 6
229940102223 injectable solution Drugs 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 2
230000001954 sterilising effect Effects 0.000 claims description 2
230000002195 synergetic effect Effects 0.000 claims 2
238000010438 heat treatment Methods 0.000 claims 1
238000001990 intravenous administration Methods 0.000 abstract description 3
239000000243 solution Substances 0.000 description 19
206010028980 Neoplasm Diseases 0.000 description 18
238000011282 treatment Methods 0.000 description 11
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
229930003268 Vitamin C Natural products 0.000 description 6
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 6
229960004919 procaine Drugs 0.000 description 6
235000019154 vitamin C Nutrition 0.000 description 6
239000011718 vitamin C Substances 0.000 description 6
208000002193 Pain Diseases 0.000 description 3
229910000085 borane Inorganic materials 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
229940063013 borate ion Drugs 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000036407 pain Effects 0.000 description 2
230000003439 radiotherapeutic effect Effects 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
MROYOSVOQDJQDE-UHFFFAOYSA-N ClO.C(C)N(CC)C(C)O Chemical compound ClO.C(C)N(CC)C(C)O MROYOSVOQDJQDE-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
-1 borate ions Chemical class 0.000 description 1
125000005619 boric acid group Chemical group 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000007803 itching Effects 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229940085991 phosphate ion Drugs 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Inorganic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

CA000354516A 1979-06-23 1980-06-20 Compose anti-tumoral et procede de preparation Expired CA1142855A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
RO97934		1979-06-23
RO7997934A RO72294A2 (fr)	1979-06-23	1979-06-23	Produit medicamenteux anticancereux et procede de preparation

Publications (1)

Publication Number	Publication Date
CA1142855A true CA1142855A (fr)	1983-03-15

Family

ID=20106169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000354516A Expired CA1142855A (fr)	1979-06-23	1980-06-20	Compose anti-tumoral et procede de preparation

Country Status (5)

Country	Link
CA (1)	CA1142855A (fr)
DE (1)	DE3023396C2 (fr)
ES (1)	ES8104912A1 (fr)
FR (1)	FR2459659A1 (fr)
RO (1)	RO72294A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0875246A1 (fr) *	1997-04-04	1998-11-04	Showa Denko Kabushiki Kaisha	Préparation pharmaceutique de dérivés d'acide ascorbique pour le traitement du cancer
RO116524B1 (ro) *	1999-05-26	2001-03-30	M. Corneliu Niculescu	Produs farmaceutic antineoplazic, uman şi veterinar, procedeu de obţinere şi metodă de tratament antineoplazic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2684323A (en) *	1950-10-21	1954-07-20	Physiological Chemicals Compan	Procaine ascorbate preparation
FR3385M (fr) *	1963-12-02	1965-06-21	Sobio Lab	Compositions thérapeutiques a base d'ascorbate de procaine.

1979
- 1979-06-23 RO RO7997934A patent/RO72294A2/fr unknown
1980
- 1980-06-16 ES ES492468A patent/ES8104912A1/es not_active Expired
- 1980-06-20 CA CA000354516A patent/CA1142855A/fr not_active Expired
- 1980-06-20 FR FR8013763A patent/FR2459659A1/fr active Granted
- 1980-06-23 DE DE19803023396 patent/DE3023396C2/de not_active Expired

Also Published As

Publication number	Publication date
FR2459659B1 (fr)	1983-05-27
ES492468A0 (es)	1981-05-16
RO72294A2 (fr)	1982-12-06
FR2459659A1 (fr)	1981-01-16
DE3023396A1 (de)	1981-01-22
DE3023396C2 (de)	1983-02-17
ES8104912A1 (es)	1981-05-16

Legal Events

Date	Code	Title	Description
2000-03-15	MKEX	Expiry

Publication	Publication Date	Title
Taylor et al.	1982	Protamine is an inhibitor of angiogenesis
Cascinu et al.	1995	Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
EP1100589B1 (fr)	2005-01-19	Utilisation de propionyle l-carnitine et d'acetyl l-carnitine dans la preparation de medicaments a action anticancereuse
JPH03169809A (ja)	1991-07-23	激痛状態の治療用医薬およびその医薬の製造方法
CN106692120A (zh)	2017-05-24	利多卡因的药物组合物及其用途
US6720011B1 (en)	2004-04-13	Injectable composition for cancer treatment
Brown et al.	1955	The mechanism of acute ferrous sulphate poisoning
Volf	1975	The effect of combinations of chelating agents on the translocation of intramuscularly deposited 239Pu nitrate in the rat
CA1142855A (fr)	1983-03-15	Compose anti-tumoral et procede de preparation
US2530480A (en)	1950-11-21	Therapeutic preparations for intramuscular and subcutaneous injection and methods of making the same
Cotter	1954	Treatment of lead poisoning by chelation
Wood et al.	1973	Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis
US9629931B2 (en)	2017-04-25	Nanoparticles for the treatment of radiation skin injury
RU2739746C9 (ru)	2021-02-15	Фармацевтическое средство для лечения артрологических заболеваний
Thompson et al.	1937	Stimulation of local antibody formation in cornea by Grenz Rays
RU2128975C1 (ru)	1999-04-20	Глазные капли "баларпан"
JPS5970615A (ja)	1984-04-21	口唇疱疹治療へのウンデシレン酸の使用
TW202114717A (zh)	2021-04-16	含有對硼苯基丙胺酸之注射液劑
RU2832338C1 (ru)	2024-12-23	Инъекционный раствор, содержащий п-боронофенилаланин
JP3775813B2 (ja)	2006-05-17	病変異常組織治療用組成物，その製造方法およびその用途
Turner et al.	1984	Diflunisal 500–750 mg versus aspirin 2600–3900 mg in the treatment of rheumatoid arthritis
WO2025221153A1 (fr)	2025-10-23	Traitement de l'hémangiome
KR20250070034A (ko)	2025-05-20	오렐라닌 제제
CN114929233A (zh)	2022-08-19	V型磷酸二酯酶抑制剂组合物、制备它们的方法以及使用它们的方法
EA041403B1 (ru)	2022-10-20	Фармацевтическое средство для лечения артрологических заболеваний